BioPharmSignal logoBioPharmSignal

Biotech News

SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

SAB Biotherapeutics (SABS)SAB BiotherapeuticsCompany update

Data will highlight deeper mechanistic insights and long-term dosing potential of SAB-142, a fully human multi-specific ATG for newly diagnosed Stage 3 T1D MIAMI, May 29, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a

Open original release

Related news

SABSSAB Biotherapeutics2026-04-15 12:00 EST

SAB BIO to Present Additional Data Supporting the Unique Profile of SAB-142 at the 2026 Immunology of Diabetes Society Congress

SABSSAB Biotherapeutics2026-04-22 11:00 EST

SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026

GPCRStructure Therapeutics2026-04-27 20:05 EST

Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions

NRIXNurix Therapeutics2026-03-23 20:05 EST

Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting

ENTAEnanta Pharmaceuticals2026-03-30 11:00 EST

Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026™, the Annual Meeting of the American Association of Immunologists (AAI)

KYMRKymera2026-06-12 11:00 EST

Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting

ENTAEnanta Pharmaceuticals2026-05-04 11:00 EST

Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026

REGNRegeneron Pharmaceuticals2026-05-15 18:09 EST

Next Generation of Scientific Leaders Awarded More Than $7 Million at the 2026 Regeneron International Science and Engineering Fair

KYMRKymera2026-03-10 11:00 EST

Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting

CLDXCelldex Therapeutics2026-06-14 14:21 EST

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting

View all latest news

SAB Biotherapeutics

SAB Biotherapeutics is a biopharmaceutical company focused on human polyclonal antibodies and immune therapy. Its platform aims to create broad immune responses for infectious and inflammatory diseases.

Recent company news

SABSSAB Biotherapeutics2026-07-07 12:00 EST

Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes

SABSSAB Biotherapeutics2026-05-29 12:00 EST

SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

SABSSAB Biotherapeutics2026-05-12 11:30 EST

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

SABSSAB Biotherapeutics2026-05-05 12:30 EST

SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET

SABSSAB Biotherapeutics2026-04-22 11:00 EST

SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026

Stock data

Close
3.44 USD
Market cap
266.1M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States